Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.

De-chu Christopher Tang

Altimmune, Inc.

Pharma Now is a monthly B2B magazine that covers trends, technological innovations, and insights in the pharmaceutical and biopharmaceutical sectors. It provides industry news and updates, interviews with leaders, market insights, and regulatory updates.

Pharma Now

Altimmune is a clinical-stage biopharmaceutical company focused on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company’s lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH. In addition, Altimmune is developing HepTcell™, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B.

Pleased to announce that our Chief Medical Office, M. Scott Harris will be attending the 6th Global NASH Congress March 2-3rd to discuss advancements in anti-obesity and NASH medications. 
#nash #nafld #liverdisease

Metric
Company Name	Altimmune, Inc.	Pharma Now
Symbol	ALT
MSH ID	COM:ALTIMMUNE	LIVE:PHARMANOW
Market	STOCKS	PRIVATE
Sector	Healthcare	Consumer Services
Industry	Biotechnology	Pharmaceuticals
Country	US	IN
Stage
Employee Count	59
Website	altimmune.com	pharmanow.live
LinkedIn	altimmune	pharma-now
Founders

Metric
Market Cap	530.35M
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue	426K
Revenue (LTM)
Revenue (NTM)
Gross Profit	-51K
EBITDA	-83.03M
Operating Income	-83.51M
Net Income	-88.45M
EPS	-1.66
Diluted EPS	-1.66
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	-48.84
Operating Profit Margin	-196.03
EBITDA Margin	-194.91
Net Profit Margin	-203.67
Return on Equity	-0.45
Return on Assets	-0.41
Return on Capital Employed	-0.42

COM:ALTIMMUNE

Altimmune, Inc.

Last Close

8.40

22/11 21:00

Market Cap

530.35M

Beta: -

Volume Today

2.20M

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	-6.74
P/B Ratio	3.38
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	1.74K
EV Multiple	-5.07

Metric
Days Sales Outstanding	5.93K
Days Payables Outstanding	10.11K
Days Inventory Outstanding	0.48
Operating Cycle	5.93K
Cash Conversion Cycle	5.89K
Asset Turnover	0.00

Metric
Operating Cash Flow	-76.00M
Free Cash Flow	-76.05M
Cash Flow to Debt	-38.39
Operating Cash Flow/Sales	-130.51
Free Cash Flow Yield	-0.11

Metric
Cash & Equivalents	135.16M
Accounts Receivable	-2.31M
Inventory
Goodwill
Debt to Capitalization	0.01
Debt to Assets
Current Ratio	12.89
Quick Ratio	16.69

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	26.35
R&D to Revenue	243.97
SG&A to Revenue	63.12